|
|
 | | | |
- close
- close
- close
- close
ZIOPHARM ONCOLOGY (ZIOP) |
Benzinga
May 16
Comment
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP)
today announced promising results from nonclinical and Phase 1 studies in
advanced melanoma using Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
Findings were presented in an oral session at the 16^th...
StreetInsider.com
Apr 9
Comment
STAAR Surgical Company (Nasdaq: STAA) 13% HIGHER; announced that first quarter revenue is expected to be approximately $18 million, which would represent approximately 16% growth. All revenue comparisons are to the same period prior year results....
StreetInsider.com
Apr 9
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ZIOPHARM+%28ZIOP%29+Issues+Ecnouraging+Update+on+IL-12+in+Breast+Cancer/8240681.html for the full story.
StreetInsider.com
Apr 5
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ZIOPHARM+Oncology+%28ZIOP%29+Eliminates+65+Workers%2C+to+Take+Charge/8235345.html for the full story.
Benzinga
Apr 4
Comment
ZIOPHARM Oncology (NASDAQ: ZIOP) shares fell 1.92% to touch a new 52-week low of $1.53. ZIOPHARM Oncology's trailing-twelve-month ROE is -160.15%.
OraSure Technologies (NASDAQ: OSUR) shares reached a new 52-week low of $5.03. OraSure's PEG...
StreetInsider.com
Mar 27
Comment
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.
52-Week High:
SAIC, Inc. (NYSE: SAI) $13.65. SAIC reported Q4 EPS of $0.54 and revs of $2.71 billion, versus analyst estimates...
TheStreet.com
Mar 27
Comment
NEW YORK (TheDeal) -- Ziopharm Oncology Inc. rebounded ever so slightly Wednesday after plunging 65% after the Charlestown, Mass.-based biotech company said its lead cancer drug, palifosfamide, flunked its Phase 3 trials.
The company's...
Benzinga
Mar 27
Comment
In a report published Wednesday, Brinson Patrick analyst Vernon Bernardino downgraded the rating on ZIOPHARM Oncology (NASDAQ: ZIOP) from Market Outperform to Market Perform, and lowered the price target from $7.00 to $1.50.
In the report,...
StreetInsider.com
Mar 26
Comment
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) 62.6% LOWER; announced that its Phase 3 trial of palifosfamide (ZIO-201) for the treatment of metastatic soft tissue sarcoma in the first-line setting (PICASSO 3) did not meet its primary endpoint of...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_1/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
